Heterojunction-driven MXenzyme biocatalysis: a progressive strategy to remodel tumor immune microenvironments for improved therapeutic efficacy
Abstract
and metal-polyphenol encapsulation, we constructed a robust nanoplatform for synergistic photothermal/enzymatic/immunotherapy. This system effectively catalyzes the generation of a cytotoxic ROS storm within tumor cells, while its catalase-like activity alleviates tumor hypoxia and augments type-II photodynamic therapy. Subsequently, the induced ICD, together with the released TLR7/8 agonist R848, promotes dendritic cell maturation and enhances T-cell infiltration, ultimately reversing the immunosuppressive TME. This work provides a promising strategy for TME reprogramming and demonstrates significant antitumor efficacy in triple-negative breast cancer, highlighting its broad potential in advancing cancer immunotherapy.
Fields of Study & Subjects
Cancer Research and Treatments
Nanoplatforms for cancer theranostics
Adenosine and Purinergic Signaling
Publication details
- Journal / source
- Journal of Materials Chemistry B
- Volume
- 14
- Issue
- 6
- Pages
- 1989–2002
- Publication date
- 1 January 2026
- Language
- EN